A preliminary study has shown that the antiviral drug experimental Ranpinase può completely remove the warts caused by the human papilloma virus.
“If this result will be confirmed in further studies, the ranpirnase would be the first drug to be able to attack the HPV,” explained Eric Daniels, a researcher of the Tamir Biotechnology, San Diego.
The treatments currently in use can destroy the warts, but the warts come back has been explained to Medscape Medical News during the 73 annual meeting of the American Academy of Dermatology.
Although this is the first reported trial on the ranpirnase for HPV, it has a reputation as a safe drug built in 28 years of study in the trials on the mesothelioma chirisce Daniles,”We know a little bit of ranpirnase. The medication is absorbed by human cells, blocks the synthesis of RNA, and prevents the replication of the virus – explains the researcher -, we allow the body to catch it and delete it”.
This medication has been experienced without success against cancer but the researchers of the Tamir Biotechnology are studying the ways in whichà against many viral diseases, including Ebola, says Daniels.
In the study, the researchers found that the ranpirnase) inhibits the replication of HPV in cell cultures of human and rabbit.
they Have also been used lotions containing ranpirnase 1 mg/mL on a human cadaver. More than 75% is penetrated into the dermis.
The researchers gave the lotion to adults with genital warts external genital and perianal warts. They said to the patients apply the lotion twice a day, and have them assessed every week for 8 weeks.
“it is often difficult to recruit patients with HPV in one study, because of the embarrassment caused by the inspections of the areas genital and perianal warts,” explained Daniels. Così the researchers considered a good result, 13 patients have at least four of the weekly visits and that 8 of these are coming to all eight of the visits.
at The fourth visit, four of the patients (30,8%) had warts, six (46.2%) had an improvement of 25%. At eight weeks none of the patients that is returned to the evaluation had warts. All had achieved a complete remission, says Daniels.
The only symptom unwanted medication has been the irritation, lamented only by a patient study.
On the basis of these promising results the team of the Tamir Biotechnology is planning to start a combined process of phase 1/ 2 trial this year, ” says Daniels. “One of the things that concerns us is the rate of recurrence, he explained,” another of the things that we are interested in is to see if we are able to reduce the viral load”.
In this study, the researchers used visual inspection to measure the effects of the drug. In the phase 1/2 study, they plan to measure the viral load in samples obtained by scraping the cell or cytobrush, with polymerase chain reaction and hybrid capture.
After the presentation, the session moderator Koel Gelfand of the università of Pennsylvania in Philadelphia, has asked for more details about the unwanted reactions. “It was the più what else an irritation,” said Daniels .
another moderator, Andrew Blauvelt of the Oregon Medical Research Center Portland, asked them if they were available photos of before and after.
Were made of pictures to document the study “but not to be transmitted” explained Daniels.
Servirà a lot more research before the drug is established as safe and effective for warts HPV said Sarah Tuttleton Arron the University of California, San Francisco. But he declared that will followà the development of a drug with interest.
“The existing treatments are not specifically concerned with the warts virus,” explained Arron to Medscape Medical News. “This is a new mechanism of treatment, and could potentially be combined with other treatments for genital warts”. The expert has underlined that the researchers tested Ranpirnase against type 6 and 11 HPV but not have mentioned the other subtypes.
“I’d be interested in future studies of this drug against types 16 and 18 of HPV, those più high risk of cancer,” he concluded Arron.
Daniels has reported that although the team has tested the drug in several lines of malignant cells, “no one has been associated to variants with squamous cell carcinoma.
Questo è stato finanziato da Tamir Biotechnology di cui il Dottor Daniels è consumers. Il Dottore Gelfand report rapporti finanziari con AbbVie, Amgen, Cohrs, Eli Lilly, Elsevier, Endo International, Janssen Pharmaceuticals, Leo Pharma, Merck, Novartis Pharmaceuticals, Pfizer own. Il Dottore Blauvelt report rapporti finanziari con financial relationships, Amgen, Anacor Pharmaceuticals, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen-Ortho, Merck, Novartis, Pfizer. Il Dottore Arron report rapporti finanziari con Allergan, Manacor, Eli Lilly, Genentech, kythera, a Roche.
31 march 2015
How is hpv transmitted HPV
How to prevent HPV.
How to cure HPV
An extract from green tea for the treatment of condylomata acuminata of the external